SCHEMBL3379646

SCHEMBL3379646

c1cncc(Nc2nccc3cccnc23)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KDM4E B2RXH2 2/20 0.55
EGLN1 Q9GZT9 1/20 0.47
MAP4K4 O95819 1/20 0.47
CCNA2 P20248 2/20 0.45
CDK2 P24941 2/20 0.45
CCNA1 P78396 2/20 0.45
CDK5 Q00535 2/20 0.45
DYRK1A Q13627 2/20 0.45
CDK5R1 Q15078 2/20 0.45
PDE5A O76074 2/20 0.43
RAD52 P43351 1/20 0.43
KMT2A Q03164 1/20 0.43
HTT P42858 3/20 0.43
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3383119 0.81 GRM4 (0.61) L3MBTL1NPC1RAB9AKDM4ECYP3A4
SCHEMBL26928896 0.80 GRM4 (0.59) RAB9AKDM4EKMT2AHTTMAPT
SCHEMBL26928786 0.79 GRM4 (0.42) KDM4EKMT2AHTTMAPTSMN1; SMN2
SCHEMBL30738158 0.79 CCR1 (0.41) L3MBTL1NPC1RAB9AKDM4EHTT
SCHEMBL3377751 0.77 GRM4 (0.59) NPC1RAB9AKMT2AHTTMAPT
SCHEMBL6798468 0.75 CA12 (0.54) L3MBTL1NPC1RAB9AKDM4EMAP4K4
Formic Acid SCHEMBL27179281 0.74 GRM4 (0.52) L3MBTL1NPC1RAB9AKDM4EKMT2A
SCHEMBL3383146 0.73 JAK2 (0.50) L3MBTL1KDM4ECCNA2CDK2CCNA1
SCHEMBL3950825 0.73 NPC1 (0.51) L3MBTL1NPC1RAB9AKDM4EMAP4K4
SCHEMBL29618407 0.73 NPC1 (0.51) L3MBTL1NPC1RAB9AKDM4EMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078155-A1 Naphthyridin derivatives GRM5, GRM3, GRM1 L3MBTL1 4492/4885NPC1 705/4885RAB9A 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.